[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].

Guan, Zhong-zhen; Liu, Dong-geng; Yu, Bao-ming; Wu, Wei-qin; Shi, De; Zhao, Yu; Wei, Yu-quan; Zou, Li-qun; Wu, Xiao-ding; Zhuang, Wen; Feng, Feng-yi; Zhang, Pin; Yu, Shi-ying; Xiong, Hui-hua; Fu, Qiang; Zheng, Shu; Huang, Jian-jin; Wu, Gang; Yang, Chuan-yong; Sun, Sheng-rong; Ruan, Qing-lan

Guan, Zhong-zhen; Liu, Dong-geng; Yu, Bao-ming; Wu, Wei-qin; Shi, De; Zhao, Yu; Wei, Yu-quan; Zou, Li-qun; Wu, Xiao-ding; Zhuang, Wen; Feng, Feng-yi; Zhang, Pin; Yu, Shi-ying; Xiong, Hui-hua; Fu, Qiang; Zheng, Shu; Huang, Jian-jin; Wu, Gang; Yang, Chuan-yong; Sun, Sheng-rong; Ruan, Qing-lan.

Affiliation

Guan ZZ; Department of Internal Medicine of Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China. zzguan@21cn.com

Zhonghua Zhong Liu Za Zhi ; 26(2): 119-21, 2004 Feb.

Article in Zh | MEDLINE | ID: mdl-15059335

Subject(s)

Antimetabolites, Antineoplastic/therapeutic use; Colorectal Neoplasms/drug therapy; Deoxycytidine/analogs & derivatives; Deoxycytidine/therapeutic use; Adult; Aged; Capecitabine; Colorectal Neoplasms/mortality; Deoxycytidine/adverse effects; Female; Fluorouracil/analogs & derivatives; Humans; Male; Middle Aged; Survival Rate

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Colorectal Neoplasms / Deoxycytidine / Antimetabolites, Antineoplastic Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: Zh Year: 2004 Type: Article

Search on Google

XML

PubMed Links